Werewolf Therapeutics Q2 2026: Going Concern Doubt, Nasdaq Delisting Risk, and Dwindling Cash
HOWL sits 81% above its 52-week low of $0.27.
Summary
Werewolf Therapeutics' Q2 2026 report reveals a going concern warning, a cash balance of just $22 million, and Nasdaq delisting risk. The company has cut over 80% of its workforce and is pursuing a strategic review.
Key Events · Earnings and Guidance · HOWL
-
Going Concern Warning
Management states there is substantial doubt about the company's ability to continue as a going concern for at least twelve months from the issuance date of these financial statements.
-
Cash Burn and Liquidity
Cash and cash equivalents fell to $22.0 million as of June 30, 2026, from $57.1 million at year-end 2025. Operating activities consumed $4.0 million during the first half of 2026.
-
Nasdaq Delisting Risk
The stock price has been below $1.00 since February 2026. With the compliance deadline of August 3, 2026, approaching and no recovery yet, delisting would severely impair liquidity and the ability to raise capital.
-
Workforce Reductions
A 64% workforce reduction occurred in February 2026, followed by an additional 36% reduction in May 2026, leaving a skeleton crew to manage the strategic review.
Analysis · HOWL · Life Sciences
The 10-Q from Werewolf Therapeutics paints a dire financial picture. With cash reserves down to $22 million, management explicitly warns of substantial doubt about the company's ability to continue as a going concern. The stock, trading at $0.49, sits far below the $1.00 Nasdaq minimum, and the August 3, 2026 compliance deadline looms without a recovery in sight. Already, the workforce has been slashed by over 80% cumulatively, the key asset was sold to Jazz for $21 million, and debt has been repaid. Lacking approved products and deep in a strategic review, the company's options are rapidly narrowing. This filing confirms the market's worst fears about its viability.
At the time of this filing, HOWL was trading at $0.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.3M. The 52-week trading range was $0.27 to $2.38. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.